HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $90 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Patrick Trucchio reiterated a Buy rating on Arrowhead Pharma (NASDAQ:ARWR) and maintained a $90 price target.
June 06, 2023 | 10:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arrowhead Pharma (ARWR) received a reiterated Buy rating and a maintained $90 price target from HC Wainwright & Co. analyst Patrick Trucchio.
The reiterated Buy rating and maintained $90 price target by HC Wainwright & Co. analyst Patrick Trucchio indicates a positive outlook for Arrowhead Pharma's stock. This news is likely to have a positive short-term impact on ARWR's stock price as it shows continued confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100